Results 91 to 100 of about 8,134 (194)

Loop Diuretic Therapy in Severe Aortic Stenosis: Marker or Mediator of Adverse Outcomes?

Clinical Cardiology, Volume 49, Issue 1, January 2026.
Masaki Miyazawa, Teruhiko Imamura
wiley   +1 more source

Ваптаны в лечении хронической сердечной недостаточности (ХСН) [PDF]

, 2013
Анализ научной медицинской литературы, содержащей информацию о новом классе препаратов "ваптаны" в терапии ...
Ефремова, О. А., Железнова, Е. А., Коррейа, Л. Л.   +2 more
core  

Interleukin-1 blockade in recently decompensated systolic heart failure: study design of the recently decompensated heart failure anakinra response trial (RED-HART) [PDF]

, 2015
Heart Failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to impaired cardiac function. The incidence of HF is increasing and represents the leading cause of hospitalization in the United States among ...
Abbate Antonio, Abouzaki Nayef, Arena Ross, BIONDI ZOCCAI, GIUSEPPE, Canada Justin, CARBONE, SALVATORE, Oddi Erdle Claudia, Valle Raleigh Juan, Van Tassell Benjamin W   +8 more
core   +1 more source

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials

Cancer Medicine, 2017
Hyponatremia is a common electrolyte disorder in cancer patients and has been associated with poor prognosis. A frequent cause of cancer‐related hyponatremia is the syndrome of inappropriate antidiuretic hormone (SIADH).
Richard J. Gralla, Fatima Ahmad, Jaime D. Blais, Joseph Chiodo III, Wen Zhou, Linda A. Glaser, Frank S. Czerwiec   +6 more
doaj   +1 more source

Tolvaptan [PDF]

Reactions Weekly, 2020
  +4 more sources

Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine [PDF]

, 2010
Patients with acute heart failure (AHF) require urgent in-hospital treatment for relief of symptoms. The main reason for hospitalization is congestion, rather than low cardiac output. Although congestion is associated with a poor prognosis, many patients
Anker SD, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner MH, Filippatos G, Follath F, Fonarow GC, Gheorghiade M, Jaarsma T, Jondeau G, McMurray JJ, Mebazaa A, Metra M, Nieminen M, Pang PS, Ponikowski P, Rhodes A, Seferovic P, Sendon JL, Stevenson LW, van Veldhuisen DJ, Zannad F   +23 more
core  

An Empirical Biomarker-based Calculator for Autosomal Recessive Polycystic Kidney Disease - The Nieto-Narayan Formula

, 2016
Autosomal polycystic kidney disease (ARPKD) is associated with progressive enlargement of the kidneys fuelled by the formation and expansion of fluid-filled cysts.
Goldberg, Itzhak D., Narayan, Prakash, Nieto, Jake A., Yamin, Michael A.   +3 more
core   +2 more sources

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease

Renal Replacement Therapy, 2018
Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disease among primary diseases in dialysis patients. Tolvaptan is known to improve increases in total kidney volume (TKV) in patients with ADPKD, thereby slowing
Shuma Hirashio, Shigehiro Doi, Takao Masaki   +2 more
doaj   +1 more source

Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus

Life
Antidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but ...
Sua Kim, Chor Ho Jo, Gheun-Ho Kim
doaj   +1 more source

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis

Frontiers in Pharmacology
Background: Tolvaptan, a selective vasopressin V2-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15 ...
Hongzhong Liu, Yongfeng Wang, Tao Liu, Yingxuan Chen, Xin Zheng, Ming Liu, Qian Zhao, Minde Zeng, Ji Jiang, Yimin Mao, Pei Hu   +10 more
doaj   +1 more source